Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Cancer care is undergoing a quiet but profound transformation, driven by technology, better understanding of disease biology, and a growing emphasis on quality of life.
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the ...
ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...
Plans to seek regulatory approval to commence a Phase III trial in the US and Canada VANCOUVER, BC, Jan. 8, 2026 /PRNewswire/ -- Sustained Therapeutics Inc. ("Sustained Therapeutics" or the "Company") ...
Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD ...
Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD upfront payment, potential milestones of ...
11hon MSN
Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...
The Urology Care Foundation and the Prostate Cancer Foundation have created a new educational guide on genetic tests to guide ...
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
Jonathan Bricker, PhD, and Fred Hutch’s Health and Behavioral Innovations in Technology (HABIT) research group developed an AI-powered chatbot app called QuitBot to help more people successfully quit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback